Virus-like particles as a potential vaccine for human papillomavirus

Papillomavirus Report

Volumn 14, Issue 2, 2003, Pages 47-51

  Ault, Kevin A ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; GAMMA INTERFERON; GENE PRODUCT; HEPATITIS B VACCINE; INTERLEUKIN 5; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; SUBUNIT VACCINE; VIRUS VACCINE;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INJECTION PAIN; NONHUMAN; PAPILLOMA; PRURITUS; RASH; REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VIRION; VIRUS GENOME; VIRUS PARTICLE; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0038634573     PISSN: 09574190     EISSN: None     Source Type: Journal    
DOI: 10.1179/095741903235001876     Document Type: Review

References (19)

1. Adams M, Borysiewicz L, Fiander A, Man S, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001;19:2549-56.
2. Murakami M, Gurski K, Steller M. Human papilloma virus vaccines for cervical cancer. J Immunother 1999;22:212-8.
3. Jansen K, Rosolowsky M, Schultz L, Markus H, et al. Vaccination with yeast-expressed cottontail papilloma virus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 1995;13:1509-14.
4. Campo M. Vaccination against papilloma virus in cattle. Clinics in Dermatology 1997;5:275-83.
5. Suzich J, Ghim S, Palmer-Hill F, White W, et al. Systemic immunization with papilloma virus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995;92:11553-7.
6. Harro C, Pang Y, Roden R, Hildesheim A, et al. Safety and immunogenicity trial in adult volunteers of a human papilloma virus 16 L1 virus like particles. J Natl Cancer Institute 2001;93:284-92.
7. Evans T, Bonnez W, Rose R, Koenig S, et al. A phase I study of recombinant virus like particle vaccine against human papilloma virus type 11 in healthy adult volunteers. J Infect Dis 2001;183:1485-93.
8. Emeny R, Wheeler C, Jansen K, Hunt W, et al. Priming of human papilloma virus type 11 humoral and cellular immune responses in college age women with a virus-like particle vaccine. J Virol 2002;76:7832-42.
9. Koutsky L, Ault K, Wheeler C, Brown D, et al. A controlled trial of a human papilloma virus type 16 vaccine. N Engl J Med 2002;347:1645-51.
10. Giroglou T, Sapp M, Lane C, Fligge C, et al. Immunological analysis of human papilloma virus capsids. Vaccine 2001;19:1783-93.
11. Crum P. The beginning of the end for cervical cancer? N Engl J Med 2002;347:1703-5.
12. Munoz N, Bosch F, de Sanjose S, Herrero R, et al. Epidemiological classification of human papilloma virus types associated with cervical cancer. N Engl J Medicine 2003;348:946-50
13. Ho G, Studentsov Y, Hall C, Bierman R, et al. Risk factors for subsequent cervicovaginal human papilloma virus and the protective roles of antibodies to the HPV 16 virus like particles. J Infect Dis 2002;186:737-42.
14. Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2001;19:877-85.
15. Hilleman M. Overview of pathogenesis, prophylaxis and therapeusis of viral hepatitis B with focus on reduction to practical applications. Vaccine 2001;19:1837-48.
16. Cassidy W, Watson B, Ioli V, Williams K, et al. A randomized trial of alternative two and three dose hepatitis B vaccination regimens in adolescents: antibody responses, safety and immunological memory. Pedatrics 2001;107:626-31.
17. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization with human papilloma virus 16 virus like particles or with the human papilloma virus L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999;73:9063-71.
18. Rose R, Lane C, Wilson S, Suzich J, et al. Oral vaccination of mice with human papilloma virus like particles induces systemic virus neutralizing antibodies. Vaccine 1999;17: 2129-35.
19. Kilbur M, afGeijerstamm V, Pukkala E, Koskela E, et al. Attack rates of human papilloma virus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV 16 vaccination. Sex Transm Infect 2000;76:13-7.